Nur Ink in 2025: The Commercial Door Is Open, but the Balance Sheet Is Still Buying Time

Getting to Know the Company

Nur Ink is no longer sitting only in the lab. In 2025 it reached several milestones that many development-stage companies never reach: the NurTex product began generating initial sales, several OEM agreements were signed, and after the reporting date the company also signed an exclusive American distribution deal with DCC and launched a new DTF ink that removes the need for adhesive powder. That is the part that is working now.

But this is still not the economics of a scaled commercial business. Revenue in 2025 was only NIS 327 thousand, while the intangible development asset climbed to NIS 11.4 million, operating cash flow was negative NIS 7.5 million, and by the time the accounts were approved the company itself wrote that its cash balance was not enough for more than 12 months without additional capital and revenues that were still not certain. So the real question in Nur Ink is no longer only whether the ink works. It is whether the company can buy itself enough time until commercialization begins to carry its own weight.

This is also where a superficial read can mislead. The bottom line looks a bit better: net loss fell to NIS 9.4 million from NIS 9.7 million, and R&D expense declined. But a meaningful part of the improvement came from capitalizing NIS 3.67 million of development costs into the balance sheet and from cost discipline, not from commercial scale. When annual revenue per employee is only around NIS 18 thousand, and the company employs 18 people of whom 14 are in R&D, it is clear that the organization still looks like an engineering platform trying to become a business.

The market layer matters too. In the April 3, 2026 trading snapshot, the share closed at 821.4 agorot, daily turnover was only NIS 5.8 thousand, and market value was roughly NIS 63 million. That is not a footnote. Even if the technology thesis improves, this level of liquidity makes it harder for the market to function as a comfortable and repeatable financing source.

The first point that needs to be on the table is that Nur Ink is no longer a pure dream-stage company, but it is also not yet a company proving operating economics. The second point is that the active bottleneck is no longer only product quality. It is the speed at which product progress turns into revenue. The third point is that the filings themselves signal that time is the company’s most expensive asset, which is why every move around warrants, extensions, and shareholder support belongs inside the main thesis, not in a legal appendix.

Events and Triggers

The key insight here is that 2025 moved Nur Ink from the stage of technological promise into the stage of initial commercial framing, but every positive trigger arrived together with either an execution test or a financing test.

Contracts exist, but commercial mass still does not

During 2025 the company signed several supply and cooperation agreements. In March it signed a multi-year DTF ink agreement with a leading global supplier, in April it signed an agreement with Print Market in Israel, and in July it signed a material OEM agreement with a veteran European company for roughly $1 million through the end of 2026. The European agreement includes quarterly minimum quantities and a mechanism that raises the ink price if the customer misses those minimums, so it offers some protection on economic quality, not just on volume.

That is the positive side. The less clean side is that in the same reporting package the company still says it has no order backlog, apart from a contractual forecast from one customer with an advance payment. In other words, 2025 proves there is commercial interest and that doors are opening, but it still does not prove that those doors have already turned into a dependable order cadence.

DCC opens America, but the value is still conditional

The DCC agreement is the single most important commercial trigger in the story right now. The memorandum of understanding was signed in October 2025, and on February 16, 2026 the parties signed the full agreement with a dedicated distribution company that will receive exclusive rights to distribute Nur Ink’s DTF ink across the Americas, subject to meeting minimum purchase targets totaling about $12 million through the end of 2028. At signing, the distributor also placed a first order and made a first payment on account.

That matters because this is no longer a technical lab test. It is a real market channel. But the two-sided reading still matters. First, exclusivity depends on meeting purchase targets. Second, part of the upside is tied to warrants that would give Nur Ink up to 20% of the distribution company, not to revenue already recognized today. And if those warrants are exercised, Nur Ink would stop being entitled to rewards from that distribution company. So here too, value may be created, but not all of it is yet directly accessible or simple at the listed-company level.

The powder-free DTF launch is a good sign, not the end of the story

In June 2025 the company announced completion of a new DTF ink that eliminates the need for adhesive powder, and in January 2026 it launched the product at Impressions Expo in the US. After the exhibition, first commercial orders were received. That is important because it suggests the company is not merely improving an existing product, but trying to change the customer workflow itself.

Still, first orders are usage proof, not scale proof. They do not yet show that the company has solved production, logistics, repeatability, or collections at a meaningful level.

The warrant moves say financing is still central

The most revealing post-balance-sheet move was not only commercial. It was financial. In February 2026 the company approved, subject to shareholder approval, a temporary reduction in the exercise price of 10/24 warrants from 800 to 744 agorot for holders willing to commit to immediate exercise. By February 25, eight holders had committed to exercise 427,040 warrants, in a move expected to bring in about NIS 3.18 million.

That point matters. The move was not designed to maximize upside for warrant holders. It was designed to accelerate cash into the company. When a development-stage company temporarily lowers the exercise price in order to shorten the route to the cash box, it is effectively telling the reader that time has become expensive.

The Series 1 extension reinforces the same message

On March 5, 2026 the board decided to pursue an extension of the Series 1 warrant exercise period to May 26, 2027 instead of May 26, 2026. The court filing described a very clear setup: as of March 4, 2026 the share price was about NIS 10.73, while the warrant exercise price was NIS 14, and none of the warrants had been exercised. The filing also said average share turnover in February 2026 was around NIS 290 thousand.

So even an existing financing instrument inside the capital structure was not working under its original terms. That does not mean the company faces an immediate crisis. It does mean the financing route has not yet settled into a self-sustaining commercial path.

Efficiency, Profitability, and Competition

The central story in 2025 is not a classic profitability improvement. It is an attempt to slow the burn rate while the company moves from lab to market. That means separating improvement that comes from better business economics from improvement that comes from accounting treatment and cost discipline.

Revenue improved, but second-half losses actually widened

Revenue rose 29% to NIS 327 thousand, which is positive, but the shape of the year matters. First-half revenue was NIS 96 thousand, while second-half revenue rose to NIS 231 thousand. In other words, 71% of annual revenue came in the second half. That shows commercialization is moving.

But profitability did not move with it. Second-half operating loss was NIS 4.9 million versus NIS 3.9 million in the first half. So for now, every commercial step still comes with support costs, pilots, and continued development spending that are heavier than the revenue being generated.

The improvement in the loss line is not as clean as it looks

R&D expense fell to NIS 3.58 million from NIS 4.48 million, and management attributes the decline mainly to an efficiency plan introduced in the second half of 2024, lower pay, and reduced headcount. That is true, but it is not the whole story. In 2025 the company capitalized NIS 3.67 million of development costs into an intangible asset, compared with NIS 4.93 million in 2024. So part of the engineering effort did not pass through the income statement at all. It moved into the balance sheet.

That is not an accounting problem by itself. It may be perfectly legitimate in a development-stage company. But it does mean the reader has to be careful not to treat the lower loss as if it came entirely from stronger sales or a lighter operating model.

Gross loss does not measure only manufacturing, but the picture is still very early even after adjustment

Cost of sales rose to NIS 1.61 million from NIS 1.25 million, and gross loss widened to NIS 1.29 million. One important nuance is that NIS 593 thousand of cost of sales is amortization of an intangible asset capitalized in prior years. So gross loss is not measuring only materials, production, and shipping. It is also carrying development cost back through the income statement.

But even after stripping that amortization out conceptually, the picture is still very early. Adjusted cost of sales would still remain far above revenue. So it is simply too soon to talk about gross margin convergence.

Competition is real, but so is differentiation

Nur Ink is not operating in a vacuum. The company itself lists established competitors in textile and wide-format inks, including DuPont, Kiian, Sensient, and Kornit. On the other hand, the filings also present a real technological differentiation argument: difficult-fabric printing capability, environmentally friendlier water-based ink, a powder-free DTF solution, and an OEM strategy that avoids building a full global direct-sales infrastructure.

What is really interesting is that the company has chosen not to go directly after end customers, but through printer makers and distributors. That lowers direct selling expense, but it also delays the point at which the economics are fully under the company’s control. A company like this can win technologically and still take time before that win turns into strong reported margins.

Cash Flow, Debt, and Capital Structure

This is where the real core of the story sits. In all-in cash flexibility terms, 2025 is another year in which Nur Ink showed that operations still do not fund themselves, so every commercial jump still depends on bridge financing.

Without external financing, this year does not end with a positive cash balance

Cash and cash equivalents rose to NIS 3.86 million at the end of 2025 from NIS 1.48 million at the end of 2024. At first glance that looks comfortable. In the correct framing, it is a funding outcome. Operating cash flow was negative NIS 7.53 million, investing cash flow was another negative NIS 130 thousand, and only NIS 10.04 million from financing kept the company above water.

That is exactly the distinction between business cash generation and financing flexibility. The business is still not generating cash. The flexibility is coming from outside.

The year-end cushion eroded quickly

The message becomes sharper in the board report. There the company says that by the report date its cash balance had already fallen to around NIS 1.6 million. That means a large part of the year-end cash had already been consumed by March 15, 2026. This explains why the February warrant step and the March shareholder support letter are not optional extras. They are part of the core liquidity story.

The liability structure is simple, but not truly easy

The company has no meaningful bank debt and no banking or non-bank credit facilities. That makes the balance sheet easier to read, but it does not mean there is no pressure. Liabilities are mainly leases, payables, and Innovation Authority royalties. Total royalty liability to the Innovation Authority stood at NIS 2.18 million, of which NIS 233 thousand was short-term, and the company is obligated to pay 3% of sales from supported products until the grants have been repaid with the relevant interest component.

So if commercialization succeeds, part of that success is already marked for repayment to the state. This is not a survival risk. But it is part of the economics of future revenue quality.

Value is being created in the balance sheet, not yet in the cash box

The largest asset on the balance sheet is the intangible asset, at NIS 11.43 million. That is the heart of the accumulated development effort. It is also the source of both strength and discomfort. On the one hand, the company has already built a meaningful IP, development, and engineering base relative to its size. On the other hand, until that asset turns into sales, margins, and cash, common shareholders mostly have an accounting asset that still requires more time and more capital.

The decline in working capital from NIS 9.08 million in 2023 to NIS 2.99 million in 2025 sharpens the same message. Even without bank debt, room for maneuver has narrowed. That is why the shareholder support commitment of up to NIS 4.5 million through June 2027 matters, but it is still not a substitute for real commercialization.

Outlook

First finding: the second half of 2025 already looked more commercial, but not more profitable.

Second finding: 2026 opened with a string of financing moves before revenue had shown scale.

Third finding: the company now sits on more agreements, but still not on an order backlog that can be called a stable base.

Fourth finding: the industrial printer is supposed to reach a beta site during 2026, but sales are targeted only for 2027. So the next product also does not solve the current year.

The implication is that 2026 looks like a bridge year with proof points, not a full breakout year. Management’s own goals for the coming year are to strengthen the economic base, continue commercialization work, complete patent registrations, sign one to two multi-year ink supply agreements, sign a development cooperation agreement with a leading raw-material company, and complete industrial-printer development ahead of commercial installations. Those are sensible goals for this stage. They also show that management is still speaking the language of platform-building, not harvest mode.

In that sense, the nearest trigger is not the printer. It is the ink. NurTex is already selling in small quantities, the powder-free DTF ink has already been launched, and the distribution and OEM agreements are already signed. If 2026 does not bring a more visible lift in recognized revenue, it will become harder to argue that the issue is only timing.

The industrial printer is the second layer of the thesis. The company expects a first prototype installation at a commercial customer during the second to third quarters of 2026, with first printer sales during the first to second quarters of 2027. That sounds promising, but it also means the printer is mostly a driver of the next chapter, not of the current year.

This is also how the market may read the story. A fast first read may focus on the DCC headlines, the new DTF product, and the OEM agreements. A deeper read will ask four harder questions: how much cash actually enters, how quickly revenue rises, whether capitalization is still flattering the P&L relative to burn, and whether 2027 can truly look different from 2026.

Risks

Financing risk is still risk number one

The company explicitly wrote that, as of the accounts approval date, its cash balance was not enough to support operations for more than 12 months without additional capital and additional revenue. That is the core risk. Yes, there is a shareholder support commitment of up to NIS 4.5 million, and there is a warrant step that may inject about NIS 3.18 million. But both are bridges, not the destination.

Agreements are not the same as revenue

In early commercialization stories it is easy to confuse a contract with a run-rate. That is a real risk here. There are material agreements, minimum purchase structures, and a meaningful American channel. Yet at the end of 2025 the company still had no order backlog and revenue remained tiny. That gap still needs to be closed in practice.

Part of the improvement in the accounts is accounting-driven

As long as the company continues capitalizing development costs at a meaningful scale, the P&L will look better than the cash flow. That is not improper, but it does create interpretation risk. Anyone looking only at the lower net loss may miss that the business is still burning cash at a high rate.

The technology execution path is not finished

The company still needs to complete the commercial development of the printer, expand ink production, and meet pilot requirements at customer sites. Even in the supply chain, not everything is fully settled. In a key resin input there is still some dependence, and management says it expects that dependence to be reduced or removed by the end of 2026.

The market risk is very practical

Weak liquidity, a Series 1 warrant that is out of the money, and low trading turnover all reduce the market’s ability to carry the company comfortably through its intermediate phase. That does not change product quality, but it does change the degree of freedom the company and its shareholders actually have.

Conclusions

Nur Ink exits 2025 with more commercial proof than before, but also with a clearer dependence on externally funded time. The supporting side of the thesis is that products are already reaching the market, that there are real OEM and distribution channels, and that DCC gives the company an important route into the Americas. The central blocker is that the gap between headline and revenue, and between development asset and cash, is still very wide. In the near term the market is unlikely to judge the story by narrative quality. It will judge it by conversion into cash and reported revenue.

Current thesis: Nur Ink now has initial commercial entry points, but 2025 was still much more a funding-and-development year than a real operating-business year.

What changed: the company is no longer just a lab-and-patent story. There are agreements, a launch, and a first order. Yet the revenue base is still too small to free the company from dependence on equity, warrants, and shareholder support.

Counter-thesis: it is possible that the market is using the wrong framework, and that if the new DTF product and the DCC distribution channel convert quickly into repeat orders, revenue may climb much faster than the current accounts suggest.

What could change the market read in the near term: actual receipt of the expected NIS 3.18 million from 10/24 warrant exercises, visible revenue conversion from the new commercial agreements, and proof that the cash balance is no longer eroding at the same pace.

Why this matters: the key question is no longer whether Nur Ink can develop ink. It is whether it can turn a large development asset into a business that can fund itself.

For the thesis to strengthen over the next two to four quarters, the company needs to show that the new agreements are generating recurring revenue, that the short-term funding bridge is really turning into cash, and that burn is moderating without choking commercialization. What would weaken the thesis is another sequence of headlines around pilots, agreements, and warrants without a visible jump in revenue and without a real easing of financing pressure.